Noble Financial reissued their buy rating on shares of Heat Biologics Inc (NASDAQ:HTBX) in a report issued on Sunday, May 14th.
Separately, Zacks Investment Research upgraded Heat Biologics from a sell rating to a hold rating in a research report on Tuesday, February 7th.
Get Heat Biologics Inc alerts:
Shares of Heat Biologics (NASDAQ HTBX) opened at 0.707 on Friday. The company has a 50-day moving average price of $0.73 and a 200-day moving average price of $0.96. The firm’s market capitalization is $25.18 million. Heat Biologics has a 12 month low of $0.52 and a 12 month high of $3.35.
Heat Biologics (NASDAQ:HTBX) last announced its quarterly earnings data on Friday, March 31st. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.05. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.13 million. Equities analysts forecast that Heat Biologics will post ($0.63) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Noble Financial Reaffirms Buy Rating for Heat Biologics Inc (HTBX)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.com-unik.info/2017/06/03/heat-biologics-inc-htbx-stock-rating-reaffirmed-by-noble-financial-updated-updated.html.
A number of institutional investors have recently bought and sold shares of the stock. Sabby Management LLC purchased a new position in Heat Biologics during the first quarter valued at approximately $2,176,000. KCG Holdings Inc. increased its position in Heat Biologics by 35.3% in the first quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 45,831 shares in the last quarter. Vanguard Group Inc. increased its position in Heat Biologics by 132.4% in the first quarter. Vanguard Group Inc. now owns 591,098 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 336,744 shares in the last quarter. Finally, Oxford Asset Management purchased a new position in Heat Biologics during the fourth quarter valued at approximately $274,000. Hedge funds and other institutional investors own 1.78% of the company’s stock.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
What are top analysts saying about Heat Biologics Inc? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts’ recommendations for for Heat Biologics Inc and related companies.